OBJECTIVE: This study aimed to examine the effectiveness of intratympanic injection of @entity801 as a nonsurgical treatment option in the treatment of @entity1 with unilateral @entity9303 who are refractory to medical treatment. STUDY DESIGN: The study design was a prospective case series. SETTING: The study was conducted at a physician's office setting in a tertiary care hospital. @entity1 : The results of 37 @entity1 who became eligible for reporting according to the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) guidelines for reporting treatment results of @entity9303 were reviewed. INTERVENTION: Intratympanic injections of a prepared @entity801 concentration of approximately 30 mg/ml were given weekly until the @entity1 reported cessation of vertigo attacks. @entity1 reclined for 45 minutes after each injection. MAIN OUTCOME MEASURES: The 1995 AAO-HNS guidelines were used in this report, and measures included pure-tone hearing results, word recognition scores, vertigo control scores, and ice-water calories after a minimum of 24 months of follow-up. RESULTS: Vertigo control was achieved in 32 @entity1 (87%). Fifteen @entity1 (41%) had complete recovery from vertigo spells, 17 @entity1 (46%) had substantial recovery, and 5 @entity1 (14%) had treatment failure requiring additional surgery to control vertigo. Hearing results showed that 21 @entity1 (72%) had unchanged or better hearing, 10 @entity1 (28%) had an average threshold shift of 10-25 dB, 4 @entity1 (11%) had a threshold shift between 16 and 25 dB, 1 @entity1 (3%) had a threshold shift between 26 and 40 dB, and 1 @entity1 (3%) had a threshold shift of > 40 dB. CONCLUSIONS: The authors found intratympanic @entity801 to be a useful alternative to surgery. The flexible treatment protocol allowed for better hearing monitoring compared to the more frequent injection schedules of other studies and yielded a lower rate of severe @entity393 . It had a higher failure rate for vertigo control and a greater amount of @entity393 than the author's experience with vestibular nerve section.

Intratympanic @entity801 injection for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin'] @entity9303 :: ('MESH:D008575', 'Disease') :: ["Meniere's disease"] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']
@entity9303 :: (MESH:D008575,Disease) :: ['Meniere's disease']
